Background/Aims: The roles and related mechanisms of RNA binding protein FUS (fused in sarcoma/translocated in liposarcoma) are unclear in numerous cancers, including hepatocellular carcinoma (HCC). Methods: Quantitative reverse transcription PCR (qRT-PCR), western blot, cell viability, transwell migration and invasion, tumor spheres formation and in vivo tumor formation assays were used to examine the effects of FUS on HCC progression in HuH7 and MHCC97 cells. Additionally, transcriptome analysis based on RNA-sequencing data, qRT-PCR, western blots, luciferase reporter and RNA binding protein immunoprecipitation (RIP) assays were used to explore the LATS1/2 (large tumor suppressor kinases 1/2)-related mechanisms contributing to FUS functions. Finally, qRT-PCR and western blot analysis were used to detect the levels of FUS and LATS1/2 in HCC and adjacent normal tissues, and the correlation between them in HCC tissues. Results: Overexpression of FUS decreased cell viability, migration, invasion and stemness. Moreover, FUS interacted and stabilized LATS1/2 stability, and thus promoted LATS1/2 expression and activated Hippo pathway. Finally, FUS and LAST1/2 levels were positively correlated and significantly down-regulated in HCC tissues. Conclusion: We demonstrate that FUS/LATS1/2 axis inhibits HCC progression via activating Hippo pathway.
Introduction
The incidence rate of hepatocellular carcinoma (HCC) ranks in the sixth, and lethality ranks in the third place worldwide [1] . And there is no obvious symptoms in the early stages and HCC holds fast development and metastasis. Although the targeted therapy and chemotherapeutics significantly improve the overall survival probability, recurrence often happens [2] . Thus, it is an urgent need to find novel biomarkers for HCC diagnosis and treatment.
Hippo pathway is an important signaling that regulates organ growth and tissue size, which plays an important role in tumor progression [3] . Typical Hippo pathway consists of Mst1/2 (mammalian sterile 20-like kinases 1/2), LATS1/2 (large tumor suppressor kinases 1/2), YAP (Yes-associated protein)/TAZ (transcriptional coactivator with PDZ -binding motif), which forms a three step kinase cascade [4] , in which LATS1/2 could phosphorylate YAP/TAZ, promote their nucleus-cytoplasm translocation and inhibit their transcriptional activity. Therefore, activating Hippo pathway or inactivating YAP/TAZ has been regarded to be a potential way to repress cancer progression. For example, verteporfin, as an inhibitor of YAP, could attenuated the resistance of BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) inhibitor in melanoma stem cells [5] , and verteporfin could induce cell apoptosis in melanoma stem cells [6] . However, efforts in this direction are frustrated by the fact that the Hippo cascade is largely undruggable [7] . While the core components of the Hippo signaling (Mst1/2/LATS1/2/YAP/TAZ) are well established, numerous additional upstream regulators of YAP activity are emerging. Such as, H-ras (HRas Proto-Oncogene, GTPase) could inhibit Hippo pathway by promoting Mst1/Mst2 heterodimerization [8] , and SnoN antagonizes the Hippo kinase complex to promote TAZ activity during breast cancer progression [9] . Therefore, it is necessary to find novel modulators of Hippo pathway, which could facilitate the development of targeting this signaling.
RNA binding proteins are a kind of protein that regulates transcripts stability and expression via directly binding to them [10] . A plenty of evidences have demonstrated the critical roles of RNA binding proteins in tumor progression. Such as, Cifdaloz et al. indicated that RNA binding protein CELF1 (CUGBP Elav-Like Family Member 1) could control a melanoma-enriched pro-oncogenic networks by a systems analysis [11] . RNA binding protein Lin28A (Lin-28 Homolog A) promotes osteocarcinoma cells progression by associating with the long noncoding RNA MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1 (Non-Protein Coding)) [12] . And RNA binding proteins could be potential targets in prostate cancer [13] . RNA binding protein FUS has been shown to interact with HSP60 (Heat Shock Protein Family 60) to promote mitochondrial damage [14] . FUS-CHOP promotes invasion in myxoid liposarcoma through a SRC (SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase)/FAK (Focal Adhesion Kinase)/RHO (Rhodopsin)/ROCK (Rho Associated Coiled-Coil Containing Protein Kinase)-dependent pathway [15] . And FUS regulates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor function and FTLD/ALS-associated behaviour via stabilizing GluA1 mRNA [16] . In HCC, miR-378 could promote the migration of HCC cells by down-regulating FUS expression [17] , which indicates the inhibitory roles of FUS in HCC progression. However, the expression level, roles and related mechanisms of FUS in HCC progression are still unclear.
Here, we aim to explore the roles and related mechanisms of FUS in HCC progression. Firstly, we found that FUS expression was significantly decreased in HCC tissues compared with normal tissues, and consistent results were acquired in HCC and normal hepatic cells. Further in vitro and in vivo experiments elucidated the inhibitory roles of FUS in HCC proliferation, migration and stemness. Mechanistically, LATS1/2 was identified as the direct target of FUS in HCC cells and the downstream effectors YAP/TAZ transcriptional activity was also reduced via FUS overexpression, and knockdown of LATS1/2 attenuated or even reversed the inhibition of FUS overexpression on HCC cells progression. Notably, FUS and LATS1/2 expression was positively correlated in HCC tissues. Therefore, our results indicate that FUS inhibits HCC progression via binding to LATS1/2 and thus activating Hippo pathway. 4 cells/200 μl in serum-free medium were added to the upper chamber. Eight hundreds microlitre (μl)medium containing 20 % FBS was used as a chemo-attractant in the bottom chamber. Cells were allowed to migrate for 24 h, and invade for 48 h. Cells migrating and invading into the underside were washed with PBS, fixed in methanol for 20 min, and stained with 0.1 % viola crystalline solution for 20 min. Five random fields from each of the triplicate were counted by using phase contrast microscopy. Quantification was performed by measuring with Microplate Reader (OD 570 nm) after being destained with glacial acetic acid.
Cell sphere formation assay
Cells with different treatment were cultured in ultra-low attachment 24-well plates (Corning, Union City, CA) at 500 cells/well with MammoCult™ Human Medium Kit (Cat#05620, Stemcell Technologies, Vancouver, BC, Canada). After 10 days culture, mammospheres number and size were detected and counted using a microscope fitted with a ruler. 
Quantitative reverse transcription PCR (qRT-PCR)

Western blotting
Detailed procedure was described elsewhere [20] . The antibodies against
and Nanog (ab21624) were purchased from Abcam, and LATS1 (sc-12494) and LATS2 (sc-23065) were purchased from Santa Cruz. p-YAP (cat # 13008) and p-TAZ (cat #59971) antibodies were purchased from Cell Signaling Technology. Primary antibody against β-actin (Cat # TA-09) and Secondary peroxidase-conjugated goat antirabbit (Cat # ZB-2306) were purchased from ZSGB-BIO, and Peroxidase-conjugated goat anti-mouse (Cat # HS201-01) was purchased from TRANSGEN BIOTECH (Beijing, China). Chemiluminescence was detected using an enhanced chemiluminescence kit (Tanon, China) followed by exposure with Tanon 5200.
RIP (RNA immunoprecipitation) assay
Cells were lysed with 25 mM Tris-HCl buffer (pH 7.5) and 100 U/ml RNase inhibitor (Sigma), and then incubated with protein-A Sepharose beads precoated with 3 μg anti-FUS antibody or control rabbit IgG for 1.5 h at 4 °C. The RNA-protein complexes were pulled-down by protein A/G agarose beads, and RNA extraction and abundance in IP were performed and detected via qRT-PCR.
mRNA stability assay HCC cells with FUS overexpression or not were cultured, and de novo RNA synthesis was blocked with 5 μg/ml of ActD (actinomycin D) (Apexbio, USA) treatment. Then total RNA was harvested at indicated time points and mRNA expression was detected by qRT-PCR. The mRNA half-life was evaluated by comparing to the mRNA levels before adding ActD.
Immunofluorescent assay
The detailed procedure was referred to the previous study [21] . Briefly, cells were cultured on glass bottom plates, washed with PBS, and then fixed with 4% paraformaldehyde in PBS for 30 min, permeabilized in 0.1% Triton X-100 for 15 min and blocked with 5% BSA in PBS for 1.5 h at room temperature. Then cells were incubated with anti-YAP antibody overnight at 4 °C, and washed with PBS and incubated with FITC- washed with PBS for three times again and observed under the confocal microscopy.
Luciferase reporter assay
Luciferase reporter assay was performed to detect YAP transcriptional and LATS1/2 promoter activity. LATS1/2 promoter sequences were introduced into the pGL3 vector (Promega), named as pGL-LATS1 and pGL-LATS2, respectively. Briefly, 8xGTIIC-luciferase plasmid (Plasmid # 34615), a YAP-responsive synthetic promoter driving luciferase expression plasmid, and pGL-LATS1/2 were co-transfected into HCC cells with FUS overexpression or not plus with β-gal (Ambion, USA) plasmid using Lipofectamine TM2000 according to the manufacturer's recommendation. After 72 h, the luciferase activity was examined. Transfection efficiency was determined using a Luciferase Reporter Assay Kit (cat. no. K801-200, BioVision, Inc., Milpitas, CA, USA). β-gal activity was determined using a β-Galactosidase Enzyme Assay System with Reporter Lysis Buffer (cat.
no. E2000, Promega Corporation) for normalization following the manufacturer's protocols.
In vivo tumor initiation and doxorubicin sensitivity assays
All animal experiments were performed with the approval of Ethics Committee for Animal Experimentation of Xuzhou Cancer Hospital. Four -six week male athymic BALB/c nude mice were purchased from Model Animal Research Center of Nanjing University, were housed and fed in standard pathogen-free conditions. For tumor-limiting dilution assays, tumor cells were mixed 1:1 with Matrigel matrix (BD Biosciences) and orthotopically implanted in the inguinal mammary gland of mice. On day 8, all mice were killed and tumor tissues were collected, weighed and fixed in 10% formalin at room temperature and embedded in paraffin for immunohistochemistry assay.
Statistical analysis
All data were presented as the mean ± SD (standard deviation). Datasets with only two groups were analyzed using a student's t-test. The differences between the groups were analyzed using One-way ANOVA with the Tukey-Kramer post-test, and P < 0.05 was considered significant.
Results
FUS expression is significantly decreased in HCC cells and tissues, and negatively correlated
with HCC progression Firstly, we examined FUS expression in HCC and adjacent normal tissues via qRT-PCR and western blot assays. qRT-PCR and western blot results showed that FUS expression is significantly decreased in HCC tissues compared with that in normal adjacent tissues (Fig. 1A and 1B) . Additionally, statistical analysis indicated that FUS expression was not correlated with sex, age, but negatively correlated with clinical stage, tumor size, lymph node metastasis ( Table 2) . FUS expression was further detected in HCC (SMMC7721, Bel-7402, MHCC97, HepG2, Hep3B, Huh-7, PLC/PRF/5) and normal hepatic (L02) cells. qRT-PCR and western blot results indicated that FUS expression was decreased in HCC cells compared with that in L02 cells (Fig. 1C and 1D ). Especially in Huh7 and HepG2 cells which were used for the following experiments. These results suggest that FUS might inhibit HCC progression.
FUS overexpression inhibits HCC cells proliferation and promotes cells apoptosis
Given the comparatively low level of FUS in Huh7 and HepG2 cells, we constructed Huh7 and HepG2 cells with FUS stable overexpression by lentivirus infection. qRT-PCR and western blot confirmed the overexpression efficiency of FUS in Huh7 and HepG2 cells ( Fig. 2A and  2B ). CCK8 assay showed that FUS overexpression significantly suppressed cell proliferation in Huh7 and HepG2 cells (Fig. 2C and 2D ). The expression of Ki67, a proliferation marker, was remarkably decreased in Huh7 and HepG2 cells with FUS overexpression (Fig. 2E and  2F) . Additionally, the effect of FUS on cell apoptosis was determined. As shown in Fig. 2G , FUS overexpression enhanced cell apoptosis in Huh7 and HepG2 cells characterized as the increase of cleaved caspase3 and cleaved PARP (Poly(ADP-Ribose) Polymerase) expression.
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Notably, the mRNA levels of anti-apoptotic genes (bcl2l1, bcl3, birc3 and bcl2a1) were also measured via qRT-PCR. Consistent result was acquired (Fig. 2H) .
FUS overexpression inhibits HCC cells migration, invasion and
epithelial-mesenchymal transition (EMT) process
We continue investigating the effects of FUS on HCC cells migration and invasion. Transwell migration and invasion analysis indicated that FUS overexpression significantly inhibited HCC cells migration and invasion (Fig. 3A and 3B ). As EMT plays promotive roles in tumor metastasis, we further explored FUS roles in HCC EMT process. As expected, the expression of epithelial marker E-cadherin was increased in HCC cells with FUS overexpression, while the expression of mesenchymal marker Vimentin was decreased ( Fig. 3C and 3D ).
FUS overexpression attenuates the stemness of HCC cells
Since FUS expression was negatively correlated with tumor size and clinical degree, and EMT process is linked with the stemness of cancer cells [22] , we speculated that FUS could also attenuate the stemness of HCC cells. Firstly, FUS expression was examined in HCC cells spheres and wild-type cells. As expected, FUS expression was remarkably decreased in HCC cells spheres compared with that in wild-type cells (Fig. 4A and 4B ). And the expression of cancer stemness markers OCT4 (POU Class 5 Homeobox 1) and Nanog (Nanog Homeobox) was indeed significantly increased in HCC cells spheres (Fig. 4B) . The expression of OCT4 and Nanog was further examined in HCC cells with FUS overexpression or not. As expected, OCT4 and Nanog expression was decreased in FUS-overexpressed cells ( Fig.  4C and 4D) . Additionally, the ability of cell sphere formation was attenuated in HCC cells with FUS overexpression characterized as decreased size and numbers of cell spheres (Fig. 4E) . Therefore, our results indicate that FUS overexpression could attenuate HCC cells stemness.
FUS directly binds to LATS1/2 and enhance LATS1/2 mRNA stability
To explore the related mechanisms contributing to FUS in prohibiting HCC progression, we tried to characterize pathways regulated by FUS. Firstly, we analyzed transcriptome of Huh7 cells with FUS stable overexpression or not based on RNA-sequencing data. Hippo signaling was shown on the top of the most upregulated pathways by FUS overexpression (Fig. 5A) , and LATS1/2 expression was markedly increased in FUS-overexpressed cells (Fig.  5B) . As FUS belongs to an RNA binding protein, bioinformatics analysis (http://starbase.sysu. edu.cn/index.php) predicted that LATS1/2 was the direct targets of FUS. LATS1/2 expression was measured in HCC (SMMC7721, Bel-7402, MHCC97, HepG2, Hep3B, Huh-7, PLC/PRF/5) and normal hepatic (L02) cells, similar results with FUS expression were obtained (Fig. 5C  and 5D ). Furthermore, overexpression of FUS enhanced LATS1/2 expression (Fig. 5E and 5F ). When FUS was overexpressed and then de novo synthesis was blocked with ActD, the decay (Fig. 5G -J) . Notably, the luciferase reporter assay showed that LATS1/2 promoter transcriptional activity was not affected by FUS overexpression (Fig. 5K) , demonstrating that FUS could not alter the transcriptional activity of LATS1/2. In addition, the FUS-binding complex was pulled down with FUS antibody, followed by examination of the bound mRNAs by qRT-PCR. As shown in Fig. 5L , RIP assays indicated that FUS associated with LATS1/2 more specifically than in the control. Therefore, these results indicated that FUS interacts with and stabilizes LATS1/2.
FUS overexpression activates Hippo pathway in a LATS1/2-dependent manner
We further investigated whether FUS overexpression indeed activated Hippo pathway through LATS1/2 expression. As expected, the expression level of p-YAP and p-TAZ was significantly increased in HCC cells with FUS overexpression, which was attenuated by LATS1/2 knockdown (Fig. 6A) . Additionally, transcriptome analysis based on RNA-sequencing showed that overexpression of FUS decreased the expression of the most targets of YAP (Fig. 6B) . Furthermore, the promotion of FUS overexpression on YAP nucleus-cytoplasm translocation was repressed by LATS1/2 knockdown (Fig. 6C and 6D ). And luciferase reporter assay showed that FUS overexpression decreased YAP transcriptional activity characterized as the decrease of 8xGTIIC-luciferase activity, a YAP-responsive synthetic promoter driving luciferase expression plasmid (Fig. 6E) , this effect was also attenuated by LATS1/2 knockdown. Notably, FUS and LATS1/2 expression was positively correlated in HCC tissues ( Fig. 6F and 6G) . 
The inhibitory effects of FUS overexpression are partly dependent on LATS1/2 expression
We tried to explore whether FUS exerts its inhibition on HCC cells progression dependent on LATS1/2 expression. As expected, the decrease of HCC cells viability, migration and invasion induced by FUS overexpression was attenuated by LATS1/2 knockdown (Fig.  7A -7C) , and consistent results were acquired in EMT process (Fig. 7D) . Furthermore, FUS overexpression-mediated attenuation on HCC cells stemness was rescued by LATS1/2 knockdown ( Fig. 7E and 7F) . Thus, our results suggest that LATS1/2 is necessary for FUS function on HCC cells progression.
FUS overexpression inhibits HCC cells progression in vivo
Finally, we evaluated whether FUS regulates HCC cells progression in vivo. We compared the capacity of Huh7 cells with FUS overexpression or not to seed tumors at limiting dilutions. Although all cell lines could form tumors at the density of 1 × 10 5 cells, FUS overexpressed cells showed a decrease of tumor size and weight ( Fig. 8A and 8B) . Notably, the tumorseeding ability of FUS-overexpressed cells was significantly decreased at the density of 1 × 10 4 (5/6 vs 3/6) and 1 × 10 3 (4/6 vs 2/6) cells. Concordantly, the staining intensity and number of Ki67, which is required for maintenance of proliferation and stemness [23] , were decreased in tumors derived from FUS-overexpressed cells (Fig. 8C and 4D ). Taken together, these results indicate that FUS overexpression inhibits HCC cells progression in vivo. 
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Discussion
Using a combination of clinical samples, biochemical, functional and bioinformatics approaches, we identified RNA binding protein FUS as a suppressor of HCC progression in vitro and in vivo. We also elucidated a mechanism through which FUS mediated, in part, its suppressive effects. We found that, in HCC cells, FUS directly bound to LATS1/2 and enhanced their mRNA stability, which inhibited the downstream effectors YAP/TAZ transcriptional activity. Notably, knockdown of LATS1/2 attenuated the suppression of FUS overexpression on HCC progression, and LATS1/2 expression was positively correlated with FUS expression in HCC tissues. To the best of knowledge, this is the first study showing the roles of FUS in HCC progression.
RNA binding proteins are abundant with ＞ 800 RNA proteins reported in human cells [24] . Given their ability to co-ordinately regulate sets of transcripts, RNA binding proteins have the potential to confer the progression of cancer cells, and their functions always depend on their targets mRNA [25] . Indeed, various studies have noted such effects on HCC progression of RNA binding proteins, such as knockdown of anillin actin binding protein [27] . The effects of RNA binding proteins were shown to arise through diverse mechanisms, including direct modulation of transcripts stability as well as regulation of alternative splicing patterns [28, 29] . In the present study, knockdown of LATS1/2 could attenuate but not reverse the suppression of FUS overexpression, this might be due to the fact that one RNA binding protein might bind to various transcripts, and one transcript could be bound by various RNA binding protein. Thus, there might other targets bound by FUS in HCC cells, and FUS binding would not be expected to impart the same effect on entire set of RNAs with which FUS interacts, this effect should be further explored. Previous study has shown that FUS-binding sites are rich in GU contents and are highly degenerative, and FUS-binding motifs of GGU, GGUG, GUGGU and CGCGC have been previously reported [30] , however, the detailed binding sites of FUS on LATS1/2 are still unclear, which would be solved in our future work. It is interesting to note that miR-378 promotes HCC cells migration by down-regulating FUS expression [17] , which suggests the inhibitory roles of FUS in HCC migration and this effect is consistent with our results. And since the stemness of cancer cells could confer chemoresistance [31] , and FUS expression has been shown to be correlated with cisplatin chemosensitivity in neuroblastoma cell lines [32] , future studies could focus on the effects of FUS on chemotherapeutics sensitivity in HCC cells. In light of our findings concerning a suppressive role for FUS in HCC progression, future studies into therapeutics methods promoting FUS expression are warranted. 
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